EW

Over the past six months, Edwards Lifesciences' stock price has fluctuated, decreasing by 6.3% from $85.26 on January 1, 2026, to $79.8580 on May 8, 2026. Key events include reporting Q4 2025 earnings and 2026 guidance in February 2026, securing FDA approval for the SAPIEN M3 mitral valve replacement system in December 2025, and reporting strong Q1 2026 earnings in April 2026. Theodora Mistras was appointed as the new CFO in May 2026. There were reports of possible bearish signals with insiders disposing of stock in May 2026. Ten-year pivotal data from the COMMENCE trial demonstrated the long-term durability of Edwards' RESILIA tissue in surgical aortic valves in May 2026.